Nabriva is excited to share a podcast interview with Dr. Thomas File Northeast Ohio Medical University (NEOMED) and Summa Health on Consultant360 highlighting a post hoc analysis of LEAP 1 and 2 studies of #lefamulin for treating community-acquired pneumonia presented at @CHEST2021. bit.ly/3b44uAO

Compelling story reinforcing the urgent need for new antibiotics; Nabriva is committed to addressing the global #AMR crisis by developing innovative #antimicrobial agents with novel mechanisms of action to treat resistant bugs of today and tomorrow

ICYMI: A replay of the Nabriva Therapeutics third quarter 2021 financial results webcast is now available: bit.ly/3qwfjEE

Today is #WorldPneumoniaDay - over the past two decades Streptococcus pneumoniae, the bacteria most responsible for #CABP, has become increasingly resistant to older classes antibiotics, which is why we are committed to advancing novel antibiotics and stronger stewardship

Our CEO Ted Schroeder is featured in this month’s #LifeScienceLeader discussing his long career in the #antibiotic space, commitment to advancing novel antibiotics to combat #AMR and fixing the flawed stewardship system.

Join us on November 18th for an on-demand fireside chat with Ted Schroeder, CEO of Nabriva Therapeutics, during the Jefferies London Healthcare Conference, now available here bit.ly/3HypApU #JEFHCLON21

It's long past time to sound the alarm on the growing crisis of #antimicrobialresistance. Nabriva Therapeutics is committed to addressing this global crisis and threat to public health. #AntibioticAwarenessWeek

Nabriva Therapeutics is committed to addressing the global #AMR crisis and strongly supports the advancement of the Pasteur Act to reinforce the urgent need for new antibiotics #pasteuract

Nabriva Therapeutics to present virtually at the H.C. Wainwright BioConnect 2022 Conference. bit.ly/3qXsMUz

ICYMI: Earlier this week Nabriva Therapeutics provided a business update and preliminary financial results for 4Q 2021. Read more here:bit.ly/3K5ghiB

Alarming report published by The Lancet reveals the magnitude of the #AMR crisis. Study shows #AntimicrobialResistance is a leading cause of death worldwide. Time for action is now. #GRAMpaper

#GoodDayBIO: AMR caused more than 1 million deaths in 2019 – we examine how we can solve that problem. Plus, USDA’s new analysis of the impact of food waste on climate, and Biden’s potential picks to fill retiring Justice Stephen Breyer’s seat. nuvi.me/kg5de6

Nabriva Therapeutics is a proud member of the AMR IndustryAlliance, working collectively within the life-science industry to combat #AMR. To learn more about united efforts from all sectors in the pharmaceutical industry, read the #AMRIndustryAlliance Progress Report here: bit.ly/3Ldg39J

We are excited to share that our CEO, Ted Schroeder, has been featured in Pharmaceutical Executive. See below for the full article.

.Vox highlights how #AMR is approaching a crisis point while detailing the current market dynamics that styme much needed antimicrobial innovation. Passing the #DISARMAct is a crucial step we can take now to help spur antimicrobial development. bit.ly/3si2T3F

Plain Language Summary of #lefamulin Phase III clinical study results now available. Read more here:

Nabriva Therapeutics has dosed its first patient in a Phase 1 clinical trial to evaluate the potential of #XENLETA in the management of bacterial infections in patients with cystic fibrosis. Read more here: bit.ly/3jHQKQl

We are excited to announce the extension of our agreement to promote and distribute SIVEXTRO® (tedizolid phosphate) in the U.S. through the end of 2026. Read more here: bit.ly/3vZMUHW

@Nabriva Therapeutics presented virtually at the H.C. Wainwright & Co., LLC Global Investment Conference this week. See full presentation located on our website: investors.nabriva.com/events-and-pre…

Today we're celebrating the achievements & spirit of the American Worker. Happy Labor Day! To learn more about the history of Labor Day, visit lnkd.in/dK9ejFj.